natgillin/translations-raw huggingface dataset:
Belgique/België/Belgien Orphan Europe Benelux Tél/Tel: +32 2 46101 36
België/Belgique/Belgien Orphan Europe Benelux Tel: +32 2 46101 36
Belgium
Belgija.
Belgium 2008-2010
Belgija 2008-2010
Belgium Belgium
Belgija Belgija
Belgium or
Belgija ili
Belgium Spain
Belgija Španjolska
Belgium.
Belgija.
Belgium/ België/Belgique/Belgien
Belgija/België/Belgique/Belgien
België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals s.a./n.v.
België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals.a./n.v.
België/Belgique/Belgien HRA Pharma Benelux Tél/Tel: +32 2 709 22 95
België/Belgique/Belgien HRA Pharma Benelux Tél/Tel: + 32 2 709 22 95
België/Belgique/Belgien Luxembourg/Luxemburg Alcon NV
België/Belgique/Belgien Luxembourg/Luxemburg Alcon- NV
België/Belgique/Belgien Luxembourg/Luxemburg Pfizer S.A./N.V.
België/Belgique/Belgien Luxembourg/Luxemburg Pfizer S.A./ N.V.
België/Belgique/Belgien MSD Belgium BVBA/SPRL Tél/Tel : 0800 38 693
België/Belgique/Belgien MSD Belgium BVBA/SPRL Tél/Tel: 0800 38 693
België/Belgique/Belgien s.a.
Be lgië /Be lgique /Be lgie n s.a.
België/Belgique/Belgien Sanofi Pasteur MSD Tél/Tel: +32 2 726.95.84
België/ Belgique /Belgien Sanofi Pasteur MSD Tél/Tel: +32 2 726.95.84
België/Belgique/Belgien/България/Česká republika/ Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/ Κύπρος/Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/ Malta/Nederland/Norge/Österreich/Polska/Portugal/ România/Slovenija/Slovenská republika/Suomi/Finland/Sverige Sun Pharmaceutical Industries Europe B.V.
België/Belgique/Belgien/България/Česká republika/ Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/ Κύπρος/Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/ Malta/NederlandNorge/ Österreich/Polska/Portugal/ România/Slovenija/Slovenská republika/Suomi/Finland/Sverige Sun Pharmaceutical Industries Europe B.V.
België/Belgique/Belgien/България/Česká republika/ Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/Κύπρος/Latvija/Lietuva/Luxembourg/Luxemb urg/Magyarország/
België/Belgique/Belgien/България/Česká republika/ Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/ Κύπρος/Latvija/Lietuva/Luxembourg/Luxemburg/ Magyarország/Malta/Nederland/Norge/Österreich/ Polska/Portugal/România/Slovenija/Slovenská republika/ Suomi/Finland/Sverige
Belimumab distributed to tissues with an overall volume of distribution of 5.29 litres.
Belimumab se raspodjeljuje u tkiva s ukupnim volumenom distribucije od 5,29 litara.
Belimumab has been designed to attach to and block a protein called BLyS which helps B lymphocytes to live longer.
Lijek belimumab namijenjen je tome da se veže na protein naziva BLyS koji pomaže u produljenju životnog vijeka B limfocita i da ga blokira.
Belimumab has been studied in a limited number of SLE patients with renal impairment.
Belimumab je ispitan na ograničenom broju SLE bolesnika s oštećenjem bubrega.
Belimumab is a human, IgG1λ monoclonal antibody, produced in a mammalian cell line (NS0) by recombinant DNA technology.
Belimumab je humano, IgG1λ monoklonsko protutijelo, proizvedeno na staničnoj liniji sisavaca (NS0) tehnologijom rekombinantne DNK.
Belimumab is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by widely distributed proteolytic enzymes.
Belimumab je protein za kojeg je očekivani metabolički put razgradnja na male peptide i pojedine aminokiseline putem široko rasprostranjenih proteolitičkih enzima.
Belimumab is not compatible with 5% glucose.
Belimumab nije kompatibilan s 5% glukozom.
Bell's palsy (a form of facial paralysis that is often reversible)
Bellova paraliza (oblik paralize lica koji je često reverzibilan)
Bellaria – 53018 Rosia – Sovicille (SI) Italy
Bellaria – 53018 Rosia – Sovicille (SI) Italija
Bellaria-Rosia 53018 Sovicille (SI) Italy
Bellaria-Rosia 53018 Sovicille (SI) Italija
Bellaria-Rosia, 53018 Sovicille (Siena), Italy
Bellaria-Rosia, 53018 Sovicille (Siena), Italija
belly
nadlaktica
belly
trbuh
belly (except for the 5 cm area around your navel) outer side of your upper arm (See picture).
trbuh (izbjegavajući područje od 5 cm oko pupka) vanjski dio nadlaktice (Pogledajte sliku).
Belly ache or stomach ache
Bol u trbuhu ili želucu
Belly ache or stomach ache
Bolovi u trbuhu ili želucu
Belly pain, upper belly pain, bloating, constipation, difficulty swallowing, dry mouth, indigestion, passing gas, stomach discomfort, swelling due to build-up of fluid around the belly
Bolovi u trbuhu, bolovi u gornjem dijelu trbuha, nadutost, zatvor, otežano gutanje, suha usta, probavne tegobe, vjetrovi, nelagoda u trbuhu, oticanje zbog nakupljanja tekućine oko trbuha
Belly, except for a 2 inch (5 centimetres) area around your belly button.
Trbuh, osim u području od 5 cm oko pupka.
Belly, except for a 5 cm (2-inch) area right around your belly button
Trbuh, osim u području od 5 cm (2 inča) oko pupka
Belly, except for a 5 cm (2-inch) area right around your belly button.
Trbuh, osim u području od 5 cm oko pupka.
Belly, except for the 2 inches (5 centimetres) around the belly button.
Trbuh, osim u području od 5 cm oko pupka.
Bell’s palsy: PT “Bell’s palsy”
Bellova paraliza: PT “Bellova paraliza”
below 3 years of age, because of safety concerns (see sections 4.4 and 5.3), or, less than 15 kg body weight, as the dose for this population has not been established in a sufficient number of patients (see section 5.1)
uzrasta ispod 3 godine, zbog sigurnosnih pitanja (vidjeti dijelove 4.4 i 5.3), ili, s manje od 15 kg tjelesne težine, jer doza za ovu populaciju nije ustanovljena na dovoljnom broju bolesnika (vidjeti dio 5.1)
Below 50 kg
manje od 50 kg
Below is a diagram that shows what the prefilled pen looks like along with the labels of the components:
U nastavku je prikazan dijagram koji pokazuje kako napunjena brizgalica izgleda zajedno s oznakama sastavnih dijelova:
Below is a list of typical symptoms associated with infusion reactions:
U nastavku slijedi popis tipičnih simptoma povezanih s reakcijama na infuziju:
Below normal oxygen content in the arterial blood (hypoxemia)
Smanjen sadržaj kisika arterijske krvi (hipoksemija)
below the level of detection by the validated RT-PCR method at 3.14 log10 RNA copies/ml, indicating no infectious virus transmission
(vrijednosti ispod razine otkrivanja validiranom RT-PCR metodom na 3,14 log10 RNA copies/ml, ukazuje na odsutnost virusa zaraze)
bemfola 150 iu/0.25 ml
bemfola 150 iu/0,25 ml
Bemfola 150 IU/0.25 ml (11 micrograms/0.25 ml) is not designed to allow the cartridge to be removed.
Bemfola 150 IU/0,25 ml (11 mikrograma/0,25 ml) je izrađena tako da ne dopušta uklanjanje uloška.
Bemfola 150 IU/0.25 ml solution for injection in a pre-filled pen
Bemfola 150 IU/0,25 ml otopina za injekciju u napunjenoj brizgalici
bemfola 150 IU/0.25 ml solution for injection in a pre-filled pen follitropin alfa
bemfola 150 IU/0,25 ml otopina za injekciju u napunjenoj brizgalici folitropin alfa
Bemfola 150 IU/0.25 ml: Each cartridge contains 150 IU (equivalent to 11 micrograms) follitropin alfa in 0.25 ml solution.
Bemfola 150 IU/0,25 ml: Svaki uložak sadrži 150 IU (što odgovara 11 mikrograma) folitropina alfa u 0,25 ml otopine.
bemfola 225 iu/0.375 ml
bemfola 225 iu/0,375 ml
Bemfola 225 IU/0.375 ml (16.5 micrograms/0.375 ml) is not designed to allow the cartridge to be removed.
Bemfola 225 IU/0,375 ml (16,5 mikrograma/0,375 ml) je izrađena tako da ne dopušta uklanjanje uloška.
Bemfola 225 IU/0.375 ml solution for injection in a pre-filled pen
Bemfola 225 IU/0,375 ml otopina za injekciju u napunjenoj brizgalici
bemfola 225 IU/0.375 ml solution for injection in a pre-filled pen follitropin alfa
bemfola 225 IU/0,375 ml otopina za injekciju u napunjenoj brizgalici folitropin alfa
Bemfola 225 IU/0.375 ml: Each cartridge contains 225 IU (equivalent to 16.5 micrograms) follitropin alfa in 0.375 ml solution.
Bemfola 225 IU/0,375 ml: Svaki uložak sadrži 225 IU (što odgovara 16,5 mikrograma) folitropina alfa u 0,375 ml otopine.
bemfola 300 iu/0.5 ml
bemfola 300 iu/0,5 ml
Bemfola 300 IU/0.50 ml (22 micrograms/0.5 ml) is not designed to allow the cartridge to be removed.
Bemfola 300 IU/0,50 ml (22 mikrograma/0,5 ml) je izrađena tako da ne dopušta uklanjanje uloška.
Bemfola 300 IU/0.50 ml solution for injection in a pre-filled pen
Bemfola 300 IU/0,50 ml otopina za injekciju u napunjenoj brizgalici
bemfola 300 IU/0.50 ml solution for injection in a pre-filled pen follitropin alfa
bemfola 300 IU/0,50 ml otopina za injekciju u napunjenoj brizgalici folitropin alfa
Bemfola 300 IU/0.50 ml: Each cartridge contains 300 IU (equivalent to 22 micrograms) follitropin alfa in 0.50 ml solution.
Bemfola 300 IU/0,50 ml: Svaki uložak sadrži 300 IU (što odgovara 22 mikrograma) folitropina alfa u 0,50 ml otopine.
bemfola 450 iu/0.75 ml
bemfola 450 iu/0,75 ml
Bemfola 450 IU/0.75 ml (33 micrograms/0.75 ml) is not designed to allow the cartridge to be removed.
Bemfola 450 IU/0,75 ml (33 mikrograma/0,75 ml) je izrađena tako da ne dopušta uklanjanje uloška.
Bemfola 450 IU/0.75 ml solution for injection in a pre-filled pen
Bemfola 450 IU/0,75 ml otopina za injekciju u napunjenoj brizgalici
bemfola 450 IU/0.75 ml solution for injection in a pre-filled pen follitropin alfa
bemfola 450 IU/0,75 ml otopina za injekciju u napunjenoj brizgalici folitropin alfa
Bemfola 450 IU/0.75 ml: Each cartridge contains 450 IU (equivalent to 33 micrograms) follitropin alfa in 0.75 mL solution.
Bemfola 450 IU/0,75 ml: Svaki uložak sadrži 450 IU (što odgovara 33 mikrograma) folitropina alfa u 0,75 ml otopine.
bemfola 75 iu/0.125 ml
bemfola 75 iu/0,125 ml
Bemfola 75 IU/0.125 ml (5.5 micrograms/0.125 ml) is not designed to allow the cartridge to be removed.
Bemfola 75 IU/0,125 ml (5,5 mikrograma/0,125 ml) je izrađena tako da ne dopušta uklanjanje uloška.
Bemfola 75 IU/0.125 ml pre-filled pen Bemfola 150 IU/0.25 ml pre-filled pen Bemfola 225 IU/0.375 ml pre-filled pen Bemfola 300 IU/0.50 ml pre-filled pen Bemfola 450 IU/0.75 ml pre-filled pen
Bemfola 75 IU/0,125 ml napunjena brizgalica Bemfola 150 IU/0,25 ml napunjena brizgalica Bemfola 225 IU/0,375 ml napunjena brizgalica Bemfola 300 IU/0,50 ml napunjena brizgalica Bemfola 450 IU/0,75 ml napunjena brizgalica
Bemfola 75 IU/0.125 ml solution for injection in a pre-filled pen
Bemfola 75 IU/0,125 ml otopina za injekciju u napunjenoj brizgalici
Bemfola 75 IU/0.125 ml solution for injection in a pre-filled pen Bemfola 150 IU/0.25 ml solution for injection in a pre-filled pen Bemfola 225 IU/0.375 ml solution for injection in a pre-filled pen Bemfola 300 IU/0.50 ml solution for injection in a pre-filled pen Bemfola 450 IU/0.75 ml solution for injection in a pre-filled pen
Bemfola 75 IU/0,125 ml otopina za injekciju u napunjenoj brizgalici Bemfola 150 IU/0,25 ml otopina za injekciju u napunjenoj brizgalici Bemfola 225 IU/0,375 ml otopina za injekciju u napunjenoj brizgalici Bemfola 300 IU/0,50 ml otopina za injekciju u napunjenoj brizgalici Bemfola 450 IU/0,75 ml otopina za injekciju u napunjenoj brizgalici
bemfola 75 IU/0.125 ml solution for injection in a pre-filled pen follitropin alfa
bemfola 75 IU/0,125 ml otopina za injekciju u napunjenoj brizgalici folitropin alfa
Bemfola 75 IU/0.125 ml: Each cartridge contains 75 IU (equivalent to 5.5 micrograms) follitropin alfa in 0.125 ml solution.
Bemfola 75 IU/0,125 ml: Svaki uložak sadrži 75 IU (što odgovara 5,5 mikrograma) folitropina alfa u 0,125 ml otopine.
Bemfola contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”.
Bemfola sadrži manje od 1 mmol natrija (23 mg) po dozi, tj. zanemarive količine natrija.
Bemfola contains less than 1 mmol sodium (23 mg) per dose, therefore it is considered essentially “sodium-free”.
Bemfola sadrži manje od 1 mmol natrija (23 mg) po dozi, tj. zanemarive količine natrija.
Bemfola dose may be increased, depending on your response.
Doza lijeka Bemfola može se povećati, što ovisi o Vašem odgovoru.
Bemfola is a biosimilar medicinal product, i.e. a medicine that has been demonstrated to be similar in quality, safety and efficacy to the reference medicinal product GONAL-f.
Bemfola je biosličan lijek, odnosno lijek koji se u svojoj kakvoći, sigurnosti i djelotvornosti pokazao sličnim referetnom lijeku GONAL-f.
Bemfola is a ‘biosimilar medicine’.
Bemfola je „biosličan lijek”.
Bemfola is expected to have no or negligible influence on the ability to drive and use machines.
Bemfola ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i strojevima.
Bemfola is given together with a medicine containing LH to stimulate the eggs to mature in the ovaries; men who have hypogonadotrophic hypogonadism (a rare hormone deficiency disease).
Bemfola se primjenjuje zajedno s lijekom koji sadrži LH za stimulaciju sazrijevanja jajašca u jajnicima; muškaraca koji boluju od hipogonadotropnim hipogonadizma (rijetke bolesti hormonalne deficijencije).
Bemfola is indicated for use in infertility (see section 4.1).
Bemfola je indicirana za primjenu kod neplodnosti (vidjeti dio 4.1).
Bemfola is intended for subcutaneous administration.
Bemfola je namijenjena supkutanoj primjeni.
Bemfola is intended to be given by injection just under the skin (subcutaneously).
Bemfola je namijenjena za potkožnu primjenu injekcijom (supkutano).
Bemfola is not indicated during breastfeeding.
Bemfola nije indicirana za vrijeme dojenja.
Bemfola is not indicated for use in children and adolescents under 18 years of age.
Bemfola nije indicirana za primjenu kod djece i adolescenata mlađih od 18 godina.
Bemfola is presented as a clear, colourless liquid for injection in a pre-filled pen.
Bemfola je bistra, bezbojna tekućina za injekciju u napunjenoj brizgalici.
Bemfola is supplied in packs with 1, 5 or 10 pre-filled pens, 1, 5 or 10 disposable needles and 1, 5 or 10 alcohol swabs.
Bemfola se isporučuje u pakiranjima s 1, 5 ili 10 napunjenih brizgalica, 1, 5 ili 10 jednokratnom igli, i 1, 5 ili 10 alkohol brisevi.
Bemfola is usually given every day.
Bemfola se obično daje svaki dan.
Bemfola may be given as a course of daily injections.
Bemfola se može davati u obliku dnevnih injekcija.
Bemfola should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a minimum of 4 months.
Lijek Bemfola treba primjenjivati u dozi od 150 IU tri puta tjedno, istodobno sa hCG, kroz najmanje 4 mjeseca.
Bemfola treatment seldom causes severe OHSS unless the medicine that is used for final follicular maturation (containing human Chorionic Gonadotropin, hCG) is administered.
Terapija lijekom Bemfola rijetko uzrokuje težak OHSS, osim kada se daje lijek za poticanje konačnog sazrijevanja folikula (koji sadrži ljudski koriogonadotropin, hCG).
benazepril HCl 2.5 mg, spironolactone 20 mg benazepril HCl 5 mg, spironolactone 40 mg benazepril HCl 10 mg, spironolactone 80 mg
benazepril HCl 2,5 mg, spironolakton 20 mg benazepril HCl 5 mg, spironolakton 40 mg benazepril HCl 10 mg, spironolakton 80 mg
benazepril HCl/spironolactone
benazepril HCl/spironolakton
Benazepril hydrochloride (HCl) (benazeprilum HCl)
Benazepril hidroklorid (HCl) (benazeprilum HCl)
Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat.
Benazepril hidroklorid je prolijek koji se hidrolizira in vivo u njegov aktivni metabolit, benazeprilat.
Benazepril hydrochloride:
Benazepril hidroklorid
Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing the synthesis of aldosterone.
Benazeprilat je visoko potentan i selektivni inhibitor angiotenzin-konvertirajućeg enzima (ACE) i tako sprečava konverziju inaktivnog angiotenzina I u aktivni angiotenzin II te tako smanjuje sintezu aldosterona.
Benazeprilat is a highly potent and selective inhibitor of angiotensin converting enzyme (ACE), thus preventing the conversion of inactive angiotensin I to active angiotensin II.
Benazeprilat je visoko potentan i selektivni inhibitor angiotenzin-konvertirajućeg enzima (ACE) I tako sprječava konverziju inaktivnog angiotenzina I u aktivni angiotenzin II.
Benazeprilat is an ‘angiotensin converting enzyme (ACE) inhibitor’.
Benazeprilat je „inhibitor enzima koji konvertiraju angiotenzin (ACE)”.
BENCHMRK 1 and 2 Pooled 48 Weeks 96 Weeks
Objedinjeni podaci BENCHMRK 1 i 2 48 tjedana 96 tjedana
BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled trials) evaluated the safety and anti-retroviral activity of ISENTRESS 400 mg twice daily vs. placebo in a combination with optimized background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of anti- retroviral therapies.
U ispitivanjima BENCHMRK 1 i BENCHMRK 2 (multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana klinička ispitivanja) ocjenjivale su se sigurnost i antiretrovirusna aktivnost lijeka ISENTRESS u dozi od 400 mg dvaput na dan naspram placeba, u kombinaciji s optimiziranom osnovnom terapijom (OBT) u bolesnika zaraženih HIV-om u dobi od 16 ili više godina, a u kojih je dokumentirana rezistencija na barem 1 lijek iz svake od 3 skupine antiretrovirusnih lijekova (NRTI, NNRTI, PI).
BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled trials) evaluated the safety and anti-retroviral activity of ISENTRESS 400 mg twice daily vs. placebo in a combination with optimized background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of anti- retroviral therapies.
U ispitivanjima BENCHMRK 1 i BENCHMRK 2 (multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana klinička ispitivanja) ocjenjivale su se sigurnost i antiretrovirusna aktivnost lijeka ISENTRESS u dozi od 400 mg dvaput na dan naspram placeba, u kombinaciji s optimiziranom osnovnom terapijom (OBT), u bolesnika zaraženih HIV-om u dobi od 16 ili više godina, a u kojih je dokumentirana rezistencija na barem 1 lijek iz svake od 3 skupine antiretrovirusnih lijekova (NRTI, NNRTI, PI).
Bend
Presavijte
BEND AND TEAR
SAVINITE I OTRGNITE
Bend the blister unit along the line where indicated.
Presavijte blister duž nazančene linije.
Bend the cap at a right angle until it snaps off.
Savijte zatvarač pod pravim kutom dok ga ne odvojite.
Bend the patch back over itself.
Presavijte iskorišteni flaster na pola.
Bend the patch in half so that the S-shaped break in the liner opens.
Savijte flaster na pola tako da se otvori S-prorez na sloju.
Bend your head slightly forward.
Nagnite glavu blago prema naprijed.
Bend your head slightly forward;
Nagnite glavu blago prema naprijed;
Bendable straw for collection of the breath samples into the corresponding breath bags
Savitljiva slamčica za sakupljanje uzoraka izdahnutog zraka u odgovarajuće vrećice za izdahnuti zrak
Bendable straw for collection of the breath samples into the corresponding breath bags
Savitljiva slamčica za sakupljanje uzoraka izdahnutog zraka u odgovarajuću vrećicu za izdahnuti zrak
Bendable straw for collection of the breath samples into the corresponding sample containers
Savitljiva slamčica za sakupljanje uzoraka izdahnutog zraka u odgovarajuće spremnike za uzorak
Bendamustine was given intravenously on Days 1 and 2 for all treatment cycles (Cycles 1-6) at 90 mg/m2/day when given in combination with Gazyvaro or 120 mg/m2/day when given alone.
Bendamustin se primjenjivao intravenski 1. i 2. dan u svim ciklusima liječenja (1. – 6. ciklus), u dozi od 90 mg/m2/dan kada se primjenjivao u kombinaciji s lijekom Gazyvaro ili u dozi od 120 mg/m2/dan kada se primjenjivao samostalno.
Benefit has also been demonstrated based on histological responses in compensated patients.
Dobrobit je također dokazana na temelju histoloških odgovora u kompenziranih pacijenata.
benefit outweighs the risk.
kad korist nadilazi rizik liječenja.
Benefit was also shown for patients with genotype 1, 4, 5 and 6 with or without cirrhosis and/or for those who had received a liver transplant.
Dokazana je i korist za bolesnike s genotipovima 1, 4, 5 i 6 bez obzira imaju li cirozu ili ne i/ili za one s presađenom jetrom.
Benefits of Defitelio were also seen in data from a patient registry in the United States, where patients with severe VOD following blood stem-cell transplantation who received Defitelio plus standard care had better outcomes than those given standard care alone, including a higher 100-day survival rate (39% versus 31%) and a higher proportion of patients whose VOD resolved (51% versus 29%).
Prednosti lijeka Defitelio uočene su također u podacima registra bolesnika dostupnog u Sjedinjenim Američkim Državama, gdje su bolesnici s teškim VOD-om koji su nakon transplantacije krvotvornih matičnih stanica primili Defitelio i standardnu dodatnu njegu imali bolje rezultate od bolesnika kojima je pružena samo standardna njega, uključujući veću 100-dnevnu stopu preživljenja (39 % u odnosu na 31 %) i veći udjel bolesnika čiji se VOD povukao (51 % u odnosu na 29 %).
Benefits of using this medicine
Koristi uporabe ovog lijeka
BeneFIX 1000 IU powder and solvent for solution for injection
BeneFIX 1000 IU prašak i otapalo za otopinu za injekciju
BeneFIX 1000 IU powder for solution for injection
BeneFIX 1000 IU prašak za otopinu za injekciju
BeneFIX 2000 IU powder and solvent for solution for injection
BeneFIX 2000 IU prašak i otapalo za otopinu za injekciju
BeneFIX 2000 IU powder for solution for injection
BeneFIX 2000 IU prašak za otopinu za injekciju
BeneFIX 250 IU powder and solvent for solution for injection
BeneFIX 250 IU prašak i otapalo za otopinu za injekciju
BeneFIX 250 IU powder and solvent for solution for injection BeneFIX 500 IU powder and solvent for solution for injection BeneFIX 1000 IU powder and solvent for solution for injection BeneFIX 2000 IU powder and solvent for solution for injection BeneFIX 3000 IU powder and solvent for solution for injection
BeneFIX 250 IU prašak i otapalo za otopinu za injekciju BeneFIX 500 IU prašak i otapalo za otopinu za injekciju BeneFIX 1000 IU prašak i otapalo za otopinu za injekciju BeneFIX 2000 IU prašak i otapalo za otopinu za injekciju BeneFIX 3000 IU prašak i otapalo za otopinu za injekciju
BeneFIX 250 IU powder and solvent for solution for injection BeneFIX 500 IU powder and solvent for solution for injection BeneFIX 1000 IU powder and solvent for solution for injection BeneFIX 2000 IU powder and solvent for solution for injection BeneFIX 3000 IU powder and solvent for solution for injection Nonacog alfa (recombinant coagulation factor IX)
BeneFIX 250 IU prašak i otapalo za otopinu za injekciju BeneFIX 500 IU prašak i otapalo za otopinu za injekciju BeneFIX 1000 IU prašak i otapalo za otopinu za injekciju BeneFIX 2000 IU prašak i otapalo za otopinu za injekciju BeneFIX 3000 IU prašak i otapalo za otopinu za injekciju nonakog alfa (rekombinantni koagulacijski faktor IX)
BeneFIX 250 IU powder for solution for injection
BeneFIX 250 IU prašak za otopinu za injekciju
BeneFIX 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection Powder and solvent for solution for injection
BeneFIX 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU prašak i otapalo za otopinu za injekciju Prašak i otapalo za otopinu za injekciju
BeneFIX 3000 IU powder and solvent for solution for injection
BeneFIX 3000 IU prašak i otapalo za otopinu za injekciju
BeneFIX 3000 IU powder and solvent for solution for injection Nonacog alfa (recombinant coagulation factor IX)
BeneFIX 3000 IU prašak i otapalo za otopinu za injekciju nonakog alfa (rekombinantni koagulacijski faktor IX)
BeneFIX 3000 IU powder for solution for injection
BeneFIX 3000 IU prašak za otopinu za injekciju
BeneFIX 500 IU powder and solvent for solution for injection
BeneFIX 500 IU prašak i otapalo za otopinu za injekciju
BeneFIX 500 IU powder for solution for injection
BeneFIX 500 IU prašak za otopinu za injekciju
BeneFIX contains recombinant coagulation factor IX, (nonacog alfa).
BeneFIX sadrži rekombinantni koagulacijski faktor IX, (nonakog alfa).